Stocks Gilead Sciences Inc

More

  • Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stock futures were sharply lower, following oil prices this morning, in a continuation of Friday's selloff and a turbulent week.

  • After another day of stock market pain, "Fast Money" traders looked for places to hide, including metals.

  • 3 safe trades in today's market

    The "Fast Money" traders give you 3 safe trades to make in today's down market.

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Traders work on the floor of the New York Stock Exchange

    U.S. stock futures were higher this morning, following oil prices which were rising in early trading. The Dow dropped nearly 300 points Tuesday as U.S. crude tanked 5.5 percent.

  • A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead reported quarterly earnings and revenue on Tuesday that beat analysts' expectations, boosted by sales of its drugs in Japan.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures fell sharply as declines in oil prices continued to weigh on investor sentiment.

  • A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

    Gilead Sciences on Friday that John Milligan, currently president and chief operating officer, will be promoted to CEO and appointed to the board of directors.

  • The headquarters of Gilead Sciences in Foster City, Calif.

    Massachusetts AG Maura Healey said the costs of two drugs "may constitute an unfair trade practice in violation of Massachusetts law."

  • Traders work on the floor of the New York Stock Exchange.

    A group of widely owned stocks may be at risk of taking a hit as investors unwind their exposure to equities amid increased volatility in 2016.

  • Bernard Tyson, Kaiser Permanente

    Kaiser Permanente CEO Bernard Tyson says a free market for prescription drugs doesn't exist in the United States.

  • Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...

  • Worried NYSE traders

    A recent sell-off pushed a group of stocks further into oversold territory, setting them up for a potential rebound, should history be any guide.

  • *First Solar up after Goldman upgrades stock to buy. After weak Chinese economic data drove stocks down sharply on Monday, the People's Bank of China on Tuesday injected $20 billion into the financial system in a bid to help its markets. Wal Mart Stores Inc shares, up 2.4 percent at $62.92, helped to lift both the Dow and S&P 500, though Monday's big selloff and...

  • *First Solar up after Goldman upgrades stock to buy. In a bid to stabilize its markets, the People's Bank of China on Tuesday injected $20 billion into the financial system. Gilead Sciences Inc rose 1.7 percent to $99.64, helping to lift the S&P 500, after its experimental hepatitis B drug was found safer than, yet as effective, as its approved treatment Viread.

  • Jan 5- Gilead Sciences Inc said its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread, in two late-stage studies. Gilead's shares rose 1 percent to $99 in premarket trading. The company plans to seek regulatory approval for TAF in the United States and Europe in the first quarter of 2016..

  • Jan 5- Gilead Sciences Inc said its once-daily experimental hepatitis B drug was found to be as effective as its approved drug, Viread, in two late-stage studies. The drug, tenofovir alafenamide, or TAF, also showed improved renal and bone safety compared with Viread, Gilead said on Tuesday. Gilead plans to submit regulatory applications for TAF in the United...

  • Biotechnology

    RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.

  • Biotech

    Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.